Vaccines Without Refrigeration: A Breakthrough for Hot Countries
British scientists have developed a vaccine against tetanus and diphtheria that can be stored without refrigeration. This innovation will help provide protection against infections in regions with hot climates and unreliable electricity supplies.
Salus
British researchers have developed a vaccine against tetanus and diphtheria that can be stored without refrigeration. This innovation aims to address the problem of vaccine spoilage in regions with hot climates and unreliable electricity, which often leads to shortages and leaves many people unprotected against dangerous infections.
The Challenge of Vaccine Storage
Modern vaccines require strict adherence to the so-called "cold chain" throughout their journey from production to patient. According to the World Health Organization, nearly half of all vaccines produced each year lose their effectiveness due to temperature fluctuations during transport and storage. This issue is especially acute in countries with tropical climates, remote areas, and conflict zones, where supply disruptions result in shortages of medical supplies and increased mortality from infectious diseases.
Trials and Effectiveness
In the first clinical trials involving 60 volunteers, the new vaccine demonstrated high efficacy and safety. One month after administration, all participants developed strong immunity to tetanus and diphtheria, comparable to that provided by standard licensed vaccines. The vaccination process did not result in any serious side effects.
Technology and Future Prospects
The development is based on the patented StablevaX technology, which stabilizes active molecules and protects them from temperature exposure. Currently, studies are underway to confirm the vaccine’s ability to remain effective without refrigeration for up to four years.
The successful results of the initial trials have paved the way for the next phase of clinical studies with a larger group of volunteers. In the future, there are plans to adapt the StablevaX technology for other types of vaccines, as well as for oncology and anti-infective drugs.
The transition to heat-stable vaccines could make immunization accessible to millions of people in remote areas and reduce the pharmaceutical industry's carbon footprint by eliminating the need for energy-intensive refrigeration equipment.
